Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer

Abstract

The arylhydrocarbon receptor (AhR) was initially identified as a member of the adaptive metabolic and toxic response pathway to polycyclic aromatic hydrocarbons and to halogenated dibenzo-p-dioxins and dibenzofurans. In the present study, we sought to determine the functional significance of the AhR pathway in pancreatic carcinogenesis. AhR expression was analysed by Northern blotting. The exact site of AhR expression was analysed by in situ hybridization and immunohistochemistry. The effects of TCDD and four selective AhR agonists on pancreatic cancer cell lines were investigated by growth assays, apoptosis assays, and induction of the cyclin-dependent kinase inhibitor p21. There was strong AhR mRNA expression in 14 out of 15 pancreatic cancer samples, weak expression in chronic pancreatitis tissues, and faint expression in all normal pancreata. In pancreatic cancer tissues, AhR mRNA and protein expression were localized in the cytoplasm of pancreatic cancer cells. TCDD and the four AhR agonists inhibited pancreatic cancer cell growth in a dose-dependent manner, and decreased anchorage-independent cell growth. DAPI staining did not reveal nuclear fragmentation and CYP1A1 and was not induced by TCDD and AhR agonists. In contrast, TCDD and AhR agonists induced the expression of the cyclin-dependent kinase inhibitor p21. In conclusion, the relatively non-toxic AhR agonists caused growth inhibition in pancreatic cancer cells with high AhR expression levels via cell cycle arrest. In addition, almost all human pancreatic cancer tissues expressed this receptor at high levels, suggesting that these or related compounds may play a role in the therapy of pancreatic cancer in the future.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

Similar content being viewed by others

Abbreviations

AHH:

arylhydrocarbon hydroxylases

AhR:

arylhydrocarbon receptor

Alkyl-PCDFs:

alkyl substituted chlorinated dibenzofurans

ARNT:

AhR nuclear translocator protein

CYP1A1:

cytochrome-P450 1A1

DIM:

diindolymethane

TCDD:

2,3,7,8-tetrachlorodibenzo-p-dioxin

6-MCDF:

6-methyl-1,3,8-trichlorodibenzofuran

8-MCDF:

8-methyl-1,3,8-trichlorodibenzofuran

6-CHDF:

6-cyclo-hexyl-1,3,8-trichlorodibenzofuran

References

  • Abe M, Yamashita J, Ogawa M . 2000 Cancer 88: 2000–2009

  • Andren-Sandberg A, Hoem D, Backman PL . 1999 Ann. Oncol. 10: 131–135

  • Angus WG, Larsen MC, Jefcoate CR . 1999 Carcinogenesis 20: 947–955

  • Astroff B, Safe S . 1989 Toxicology 59: 285–296

  • Becher H, Flesch-Janys D, Kauppinen T, Kogevinas M, Steindorf K, Manz A, Wahrendorf J . 1996 Cancer Causes Control 7: 312–321

  • Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C, Pesatori AC . 2001 Am. J. Epidemiol. 153: 1031–1044

  • Bertazzi PA, Zocchetti C, Guercilena S, Consonni D, Trioni A, Landi MT, Pesatori AC . 1997 Epidemiology 8: 646–652

  • Büchler M, Friess H, Schultheiss KH, Gebhardt C, Kubel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, Muller G, Schulz G, Beger HG . 1991 Cancer 68: 1507–1512

  • Buckingham J, Macdonald F . 1997 Dictionary of Organic Compounds Sixth edn New York: Chapman and Hall Electronic Publishing Division

    Google Scholar 

  • Carver LA, Hogenesch JB, Bradfield CA . 1994 Nucleic Acids Res. 22: 3038–3044

  • Chen I, McDougal A, Wang F, Safe S . 1998 Carcinogenesis 19: 1631–1639

  • Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI . 1999 Cancer Lett. 139: 199–205

  • Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL . 1998 J. Biol. Chem. 273: 3838–3847

  • Denison MS, Fisher JM, Whitlock Jr JP . 1988 J. Biol. Chem. 263: 17221–17224

  • Dolwick KM, Schmidt JV, Carver LA, Swanson HI, Bradfield CA . 1993 Mol. Pharmacol. 44: 911–917

  • Dreisbach RH, Robertson WO . 1987 Handbook of Poisoning: prevention, diagnosis and treatment 12th edn Norwalk, Conn, USA: Appleton & Lange

    Google Scholar 

  • Elferink CJ, Gasiewicz TA, Whitlock Jr JP . 1990 J. Biol. Chem. 265: 20708–20712

  • Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ . 1996 Toxicol. Appl. Pharmacol. 140: 173–179

  • Fingerhut MA, Halperin WE, Marlow DA, Piacitelli LA, Honchar PA, Sweeney MH, Greif AL, Dill PA, Steenland K, Suruda AJ . 1991 N. Engl. J. Med. 324: 212–218

  • Friess H, Buchler M, Kruger M, Beger HG . 1992 Pancreas 7: 516–521

  • Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL, Korc M . 1993 Cancer Res. 53: 2704–2707

  • Geiger LE, Neal RA . 1981 Toxicol. Appl. Pharmacol. 59: 125–129

  • Goodman LS, Gilman A, Gilman AG . 1990 Goodman and Gilman's: The Pharmacological Basis of Therapeutics 8th edn New York: Pergamon Press

    Google Scholar 

  • Hankinson O . 1995 Annu. Rev. Pharmacol. Toxicol. 35: 307–340

  • Harris M, Zacharewski T, Astroff B, Safe S . 1989 Mol. Pharmacol. 35: 729–735

  • Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K . 1994 Carcinogenesis 15: 801–806

  • Hayes WJ . 1982 Pesticides Studied in Man Baltimore: Williams and Wilkins

    Google Scholar 

  • Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O . 1991 Science 252: 954–958

  • Huff J, Lucier G, Tritscher A . 1994 Annu. Rev. Pharmacol. Toxicol. 34: 343–372

  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 1987 Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. This publication represents the views and expert opinions of an IARC ad-hoc Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 10–18 March 1987 Lyon, France and Geneva, Switzerland: World Health Organization International Agency for Research on Cancer Distributed by the World Health Organization Distribution and Sales Service

  • International Agency for Research on Cancer and World Health Organization. 1987 Overall evaluations of carcinogenecity: an updating of IARC monographs 1–42: Lyon, France: International Agency for Research on Cancer

  • Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H . 1999 Biochem. Biophys. Res. Comm. 256: 462–468

  • Johnson ES . 1991 Crit. Rev. Toxicol. 21: 451–463

  • Jones PB, Durrin LK, Fisher JM, Whitlock Jr JP . 1986 J. Biol. Chem. 261: 6647–6650

  • Kashani M, Steiner G, Haitel A, Schaufler K, Thalhammer T, Amann G, Kramer G, Marberger M, Scholler A . 1998 Prostate 37: 98–108

  • Kobayashi A, Sogawa K, Fujii-Kuriyama Y . 1996 J. Biol. Chem. 271: 12310–12316

  • Kojima T, Tanaka T, Mori H . 1994 Cancer Res. 54: 1446–1449

  • Kolluri SK, Weiss C, Koff A, Gottlicher M . 1999 Genes Dev. 13: 1742–1753

  • Krishnan V, Porter W, Santostefano M, Wang X, Safe S . 1995 Mol. Cell. Biol. 15: 6710–6719

  • Krishnan V, Wang X, Safe S . 1994 J. Biol. Chem. 269: 15912–15917

  • Kuil CW, Brouwer A, van der Saag PT, van der Burg B . 1998 J. Biol. Chem. 273: 8829–8834

  • Landers JP, Bunce NJ . 1991 Biochem. J. 276: 273–287

  • Ledirac N, Delescluse C, Lesca P, Piechocki MP, Hines RN, de Sousa G, Pralavorio M, Rahmani R . 2000 Toxicol. Appl. Pharmacol. 164: 273–279

  • Li W, Harper PA, Tang BK, Okey AB . 1998 Biochem. Pharmacol. 56: 599–612

  • Ma Q, Whitlock Jr JP . 1996 Mol. Cell. Biol. 16: 2144–2150

  • Matsushita N, Sogawa K, Ema M, Yoshida A, Fujii-Kuriyama Y . 1993 J. Biol. Chem. 268: 21002–21006

  • McDougal A, Gupta MS, Morrow D, Ramamoorthy K, Lee JE, Safe SH . 2001 Breast Cancer Res. Treat. 66: 147–157

  • McDougal A, Wilson C, Safe S . 1997 Cancer Lett. 120: 53–63

  • Morse MA, LaGreca SD, Amin SG, Chung FL . 1990 Cancer Res. 50: 2613–2617

  • Norman J, Franz M, Schiro R, Nicosia S, Docs J, Fabri PJ, Gower Jr WR . 1994 J. Surg. Res. 57: 33–38

  • Oikawa K, Ohbayashi T, Mimura J, Iwata R, Kameta A, Evine K, Iwaya K, Fujii-Kuriyama Y, Kuroda M, Mukai K . 2001 Cancer Res. 61: 5707–5709

  • Parker SL, Tong T, Bolden S, Wingo PA . 1997 CA Cancer J. Clin. 47: 5–27

  • Patikoglou G, Burley SK . 1997 Annu. Rev. Biophys. Biomol. Struct. 26: 289–325

  • Poland A, Glover E . 1979 Cancer Res. 39: 3341–3344

  • Poland A, Knutson JC . 1982 Annu. Rev. Pharmacol. Toxicol. 22: 517–554

  • Poland AP, Glover E, Robinson JR, Nebert DW . 1974 J. Biol. Chem. 249: 5599–5606

  • Quattrochi LC, Vu T, Tukey RH . 1994 J. Biol. Chem. 269: 6949–6954

  • Ramamoorthy K, Gupta MS, Sun G, McDougal A, Safe SH . 1999 Carcinogenesis 20: 115–123

  • Reyes H, Reisz-Porszasz S, Hankinson O . 1992 Science 256: 1193–1195

  • Rininger JA, Stroffregen DA, Babish JG . 1997 Chemosphere 34: 1557–1568

  • Rowlands C, Krishnan V, Wang X, Santostefano M, Safe S, Miller WR, Langdon S . 1993 Cancer Res. 53: 1802–1807

  • Roy NK, Wirgin I . 1997 Arch. Biochem. Biophys. 344: 373–386

  • Safe S . 2001 Toxicol. Lett. 120: 1–7

  • Safe S, Wang F, Porter W, Duan R, McDougal A . 1998 Toxicol. Lett. 102, 103: 343–347

  • Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR . 1988 Genes Dev. 2: 1144–1154

  • Sax NI, Lewis RJ . 1989 Dangerous Properties of Industrial Materials 7th edn New York: Van Nostrand Reinhold

    Google Scholar 

  • Sittig M . 1985 Handbook of Toxic and Hazardous Chemicals and Carcinogens 2nd edn Park Ridge, NJ, USA: Noyes Publications

    Google Scholar 

  • Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR . 1990 J. Natl. Cancer Inst. 82: 1107–1112

  • Skene SA, Dewhurst IC, Greenberg M . 1989 Hum. Toxicol. 8: 173–203

  • Spink BC, Fasco MJ, Gierthy JF, Spink DC . 1998 J. Cell Biochem. 70: 289–296

  • Steenland K, Piacitelli L, Deddens J, Fingerhut M, Chang LI . 1999 J. Natl. Cancer Inst. 91: 779–786

  • Stoewsand GS, Anderson JL, Munson L . 1988 Cancer Lett. 39: 199–207

  • Strahle U, Schmid W, Schutz G . 1988 EMBO J. 7: 3389–3395

  • Sun G, Safe S . 1997 Cancer Chemother. Pharmacol. 40: 239–244

  • Sutter TR, Guzman K, Dold KM, Greenlee WF . 1991 Science 254: 415–418

  • Swanson HI, Bradfield CA . 1993 Pharmacogenetics 3: 213–230

  • Takahashi Y, Nakayama K, Shimojima T, Itoh S, Kamataki T . 1996 Eur. J. Biochem. 242: 512–518

  • Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H . 1993 Am. J. Gastroenterol. 88: 1928–1933

  • Vang O, Jensen MB, Autrup H . 1990 Carcinogenesis 11: 1259–1263

  • Vickers PJ, Dufresne MJ, Cowan KH . 1989 Mol. Endocrinol. 3: 157–164

  • Wang F, Wang W, Safe S . 1999 Biochemistry 38: 11490–11500

  • Wang X, Rosengren R, Morrison V, Santostefano M, Safe S . 1992 Biochem. Pharmacol. 43: 1635–1642

  • Wang X, Thomsen JS, Santostefano M, Rosengren R, Safe S, Perdew GH . 1995 Eur. J. Pharmacol. 293: 191–205

  • Wattenberg LW, Loub WD . 1978 Cancer Res. 38: 1410–1413

  • Weiss C, Kolluris K, Kiefer F, Gottlicher M . 1996 Exp. Cell Res. 226: 154–163

  • Windholz M, Budavari S, Blumetti RF, Otterbein ES . 1983 The Merck Index: an encyclopedia of Chemicals, Drugs and Biologicals 10th edn Rahway, NJ, USA: Merck

    Google Scholar 

  • Wormke M, Castro-Rivera E, Chen I, Safe S . 2000 J. Steroid Biochem. Mol. Biol. 72: 197–207

  • Wu L, Whitlock Jr JP . 1992 Proc. Natl. Acad. Sci. USA 89: 4811–4815

  • Zacharewski TR, Bondy KL, McDonell P, Wu ZF . 1994 Cancer Res. 54: 2707–2713

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Helmut Friess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koliopanos, A., Kleeff, J., Xiao, Y. et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 21, 6059–6070 (2002). https://doi.org/10.1038/sj.onc.1205633

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205633

Keywords

This article is cited by

Search

Quick links